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Summary
Background Reducing deaths from hypertensive disorders of pregnancy is a global priority. Low dietary calcium 
might account for the high prevalence of pre-eclampsia and eclampsia in low-income countries. Calcium 
supplementation in the second half of pregnancy is known to reduce the serious consequences of pre-eclampsia; 
however, the effect of calcium supplementation during placentation is not known. We aimed to test the hypothesis 
that calcium supplementation before and in early pregnancy (up to 20 weeks’ gestation) prevents the development 
of pre-eclampsia
Methods We did a multicountry, parallel arm, double-blind, randomised, placebo-controlled trial in South Africa, 
Zimbabwe, and Argentina. Participants with previous pre-eclampsia and eclampsia received 500 mg calcium or 
placebo daily from enrolment prepregnancy until 20 weeks’ gestation. Participants were parous women whose most 
recent pregnancy had been complicated by pre-eclampsia or eclampsia and who were intending to become pregnant.
All participants received unblinded calcium 1·5 g daily after 20 weeks’ gestation. The allocation sequence (1:1 ratio) 
used computer-generated random numbers in balanced blocks of variable size. The primary outcome was 
pre-eclampsia, defined as gestational hypertension and proteinuria. The trial is registered with the Pan-African 
Clinical Trials Registry, number PACTR201105000267371. The trial closed on Oct 31, 2017.
Findings Between July 12, 2011, and Sept 8, 2016, we randomly allocated 1355 women to receive calcium or placebo; 
331 of 678 participants in the calcium group versus 320 of 677 in the placebo group became pregnant, and 298 of 
678 versus 283 of 677 had pregnancies beyond 20 weeks’ gestation. Pre-eclampsia occurred in 69 (23%) of 
296 participants in the calcium group versus 82 (29%) of 283 participants in the placebo group with pregnancies 
beyond 20 weeks’ gestation (risk ratio [RR] 0·80, 95% CI 0·61–1·06; p=0·121). For participants with compliance 
of more than 80% from the last visit before pregnancy to 20 weeks’ gestation, the pre-eclampsia risk was 30 (21%) 
of 144 versus 47 (32%) of 149 (RR 0·66, CI 0·44–0·98; p=0·037). There were no serious adverse effects of 
calcium reported.
Interpretation Calcium supplementation that commenced before pregnancy until 20 weeks’ gestation, compared with 
placebo, did not show a significant reduction in recurrent pre-eclampsia. As the trial was powered to detect a large 
effect size, we cannot rule out a small to moderate effect of this intervention.
Funding The University of British Columbia, a grantee of the Bill & Melinda Gates Foundation; UNDP–UNFPA–
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and the Centre for Intervention Science in Maternal and Child Health.
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Introduction
Hypertension is estimated to complicate 5% of all 
pregnancies and 11% of first pregnancies, and half of 
these cases are associated with pre-eclampsia (gestational 
hypertension plus proteinuria).1 Hypertensive disorders 
of pregnancy are the direct cause of death of about 
30 000 women annually,2 or approximately 14% of maternal 
deaths,3 most of which occur in low-income countries. In a 
survey of 29 countries in Africa, Asia, Latin America, and 
the Middle East, 25∙9% of women with severe maternal 
outcomes (ie, maternal death or near miss death) had 
pre-eclampsia or eclampsia, which was the direct cause 
of 20% of reported maternal deaths in these country 
settings.4 Therefore, reducing maternal mortality and 
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mor bidity from hypertensive disorders is a global priority.
Although pre-eclampsia is considerably more prevalent 
in disadvantaged than advantaged populations, two striking 
exceptions have been identified. Over 50 years ago, a low 
prevalence of pre-eclampsia was reported in Ethiopia, 
where the local diet contained high levels of calcium.5 
Similarly, in 1980 it was observed that among Mayan 
Indians in Guatemala, who traditionally soaked their 
staple corn in lime (calcium hydroxide) water before cook-
ing, pre-eclampsia was uncommon.6 These observa tions 
stimulated research interest in the concept that the link 
between pre-eclampsia and poverty might be a dietary 
deficiency of calcium.
The hypothesis that calcium supplementation during 
pregnancy might reduce the prevalence of pre-eclampsia 
was tested in several randomised controlled trials (RCTs) 
beginning in the late 1980s.7–15 In 2001, WHO did a large 
RCT (n=8325) of calcium supplementation (1·5 g per day) 
from 20 weeks’ gestation among pregnant women with 
low calcium intake.16 Although the supplement did not 
prevent pre-eclampsia (risk ratio [RR], 0·91; 95% CI, 
0·69–1·19), it reduced its severity (0·76; 0·66–0·89), severe 
maternal morbidity and mortality (0·80; 0·70–0·91), and 
neonatal mortality (0·70; 0·56–0·88).16
A meta-analysis of 13 RCTs in a Cochrane systematic 
review found that calcium supplementation of at least 
1 g daily from mid-pregnancy (20 weeks) was associated 
with a 55% reduction in pre-eclampsia.17 How ever, the 
magnitude of this effect was thought to be over-estimated 
owing to the small study effects.17 The review highlighted 
that the reduction in pre-eclampsia was greatest in the 
subgroup of women at high risk of pre-eclampsia, and 
those with low dietary calcium intake. It also found a 
reduction in the composite outcome of maternal death or 
serious morbidity with calcium supplementation.
A nested study within the large WHO trial of calcium 
supplementation during the second half of pregnancy 
(ie, >20 weeks) failed to show an effect on biochemical 
measures commonly elevated in pre-eclampsia (ie, serum 
urate, platelet count, and urine protein:creatinine ratio).18 
This absence of effect was consistent with the findings of 
no difference in proteinuria in the main WHO trial 
(8312 participants, RR 1·01; 95% CI 0·88–1·15).16 We 
hypothesised that calcium supplementation in the 
second half of pregnancy reduces blood pressure, and 
thus the diagnosis and severe manifestations of pre-
eclampsia, without having a sub stantial effect on the 
underlying pathology (eg, defective placentation in early 
pregnancy). If our hypothesis is correct, an inadequate 
calcium intake before and during early pregnancy might 
place certain populations at higher risk of pre-eclampsia.
To our knowledge, no randomised trials have specifically 
evaluated the effect of calcium supplementation com-
menced before pregnancy on pre-eclampsia. In this paper, 
we report the findings of a randomised placebo-controlled 
trial among women who had pre-eclampsia or eclampsia 
in their previous pregnancy, designed to establish whether 
calcium supplementation started before pregnancy and 
continued during the first half of pregnancy might reduce 
the subsequent development of pre-eclampsia and other 
adverse outcomes, despite high dose supplementation to 
both groups after 20 weeks’ gestation.
Research in context
Evidence before this study
We searched PubMed for articles published in English between 
Jan 1, 1980, and Dec 31, 2017, reporting the effect of 
prepregnancy or early pregnancy calcium supplementation on 
pre-eclampsia. Among 185 records, we identified one 
randomised controlled trial with 60 participants that evaluated a 
calcium-containing antioxidant supplement commenced at 
8 to 12 weeks’ gestation compared with placebo. Participants 
were pregnant women who screened positive for low 
antioxidant status. This small study reported reductions in 
pre-eclampsia (two of 29 vs nine of 31) and miscarriage (none of 
29 vs eight of 31) in favour of the intervention. However, as the 
intervention comprised multiple nutrients and the study was 
underpowered to detect a difference in pre-eclampsia, the 
findings with respect to calcium supplementation in early 
pregnancy are difficult to interpret. Evidence from a Cochrane 
systematic review of randomised trials shows that calcium 
supplementation after 20 weeks of pregnancy reduces the 
serious consequences of pre-eclampsia and the prevalence of 
pre-eclampsia. The effect was mostly shown in the smaller trials 
contributing to the review, whereas in a large WHO-led trial it 
was not significant. We hypothesised that, as the pathological 
process of pre-eclampsia might evolve early on in pregnancy, 
calcium supplementation from 20 weeks’ gestation could be too 
late to have a substantial effect on this condition.
Added value of this study
This study is the first randomised trial to our knowledge to 
report the effects of calcium supplementation before and in 
early pregnancy, when pre-eclampsia is thought to develop. 
Although our primary findings on pre-eclampsia are not 
significant, they might justify further research into the relation 
between early pregnancy calcium intake and pre-eclampsia.
Implications of all the available evidence
The overall benefits of calcium supplementation throughout 
pregnancy would be the sum of any prepregnancy and early 
pregnancy effects plus those shown in previous studies of 
calcium supplementation after 20 weeks’ gestation. Findings 
from our study, with appropriate recognition of their absence of 
significance, should be considered together with all other 
available evidence on the benefits of adequate calcium intake 
for pregnant women and the general population, in 
determining the cost and benefits of strategies to improve 
calcium intake at a population level.
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Methods
Study design
This was a multicentre, parallel arm, double blind, ran-
domised, placebo-controlled trial, done in South Africa, 
Zimbabwe, and Argentina. In South Africa (Frere and 
Cecilia Makiwane Hospitals in East London; Chris Hani 
Baragwanath Hospital Johannesburg; Groote Schuur, 
Mowbray Maternity and Tygerberg Hospitals in 
Cape Town) and Zimbabwe (Harare Maternity and 
Mbuya Nehanda Maternity Hospitals, Harare) sites 
were state secondary or tertiary referral hospitals with 
large obstet ric services (4000 to 20 000 births per year) 
providing comprehensive obstetric care, serving urban 
and rural lower-income populations. The sites in 
Argentina com prised three maternity hospitals, one in 
the province of Tucumán and two in Buenos Aires: 
the Institute of Maternity and Gynecology of Our Lady 
of Mercedes is located in the capital city of Tucumán 
province and it is the public referral maternity hospital 
of northwest Argentina with around 9000 deliveries 
each year; Hospital Italiano and CEMIC are private 
third-level maternity hospitals in Buenos Aires, each 
with around 2000 deliveries per year.
The protocol of this study was approved by the Re-
search Project Review Panel of the UNDP–UNFPA–
UNICEF–WHO–World Bank Special Programme of 
Research, Development and Research Training in Human 
Repro duction at the Department of Reproductive Health 
and Research of WHO, and the WHO Research Ethics 
Review Committee, Geneva, Switzerland. Ethical approval 
was obtained from the appropriate national and insti-
tutional ethics review bodies applicable to each study site 
before the start of the trial. Data management procedures 
were compliant with good clinical practice.
The protocol of this trial is published online in 
The Lancet (protocol 11PRT/4028).19
Participants
We used several approaches to identify potentially eligible 
women: direct searching of hospital records; prospective 
identification of women with, or after, pregnancies com-
plicated by pre-eclampsia or eclampsia to recruit them at 
a future date; and raising community awareness through 
posters, community outreach visits, and radio interviews. 
Details of recruitment and retention strategies are 
reported elsewhere.20
Participants were parous women whose most recent 
pregnancy had been complicated by pre-eclampsia or 
eclampsia and who were intending to become preg-
nant. All participants provided informed written consent. 
Women were not eligible for the trial if they were younger 
than 18 years old; were already pregnant; were taking 
calcium supplementation; had chronic hypertension 
with persistent proteinuria; had a history or symptoms of 
urolithiasis, renal disease, or parathyroid disease; were 
not in a sexual relationship; were using long-term contra-
ception (eg, hormonal injections or implant, intrauterine 
contraceptive device, or sterilisation); or were unwilling 
to give informed consent.
Randomisation and masking
The random allocation sequence was generated centrally 
at WHO headquarters in Geneva, Switzerland, using 
computer-generated random numbers in a ratio of 1:1 
and in balanced blocks of variable size, stratified by site. 
Participants, care providers, and outcome assessors were 
all masked to group allocation. Calcium and placebo 
tablets were packed in identical 12-week treatment 
bottles, each containing 84 tablets. Participants were 
randomly assigned to a calcium supplementation or 
placebo group. The calcium group received one chewable 
tablet con taining 500 mg elemental calcium (as calcium 
carbonate) daily from prepregnancy randomisation 
until 20 weeks’ gestation. The placebo tablet was 
indistinguish able from the calcium tablet in appearance 
and taste. At enrolment, allocation was done using an 
online service hosted by WHO, which allocated the next 
available treatment pack number from the site’s supply. 
At sub sequent visits, the same online service was used to 
allocate an appropriate pack number, which ensured 
continuation of the allocated treatment without revealing 
group allocation.
After 20 weeks’ gestation, all participants received 
open-label calcium tablets. Three bottles of 84 tablets 
each were supplied at a time, which was sufficient for a 
12-week period (ie, from 20 weeks’ to 32 weeks’ gestation 
and from 32 weeks’ gestation until birth).
Procedures
The trial methods built on those used in the WHO trial of 
calcium supplementation during the second half of 
pregnancy that was done among pregnant women in 
similar settings,16 incorporating experiences and lessons 
learnt.
Participants were asked to chew their allocated tablet in 
the evening at a time distant from taking food or iron 
supplements. They were en couraged not to take any 
additional calcium supple ments. For those participants 
who needed analgesics, para cetamol was recommended, 
and for those needing antacids, a non-calcium-based 
antacid was recommended.
The rationale for the calcium dosage selected was based 
on a dietary calcium survey done to inform the design of 
the WHO trial of calcium supplementation during the 
second half of pregnancy,16 which showed that pregnant 
primiparous women in Argentina had a median daily 
dietary calcium intake of 481 mg and in South Africa 
a median daily dietary calcium intake of 567 mg.20 
Supplementation with 500 mg of calcium per day could 
thus achieve a median daily intake of about 1000 mg. This 
amount would approximate the daily calcium intake 
among pregnant women in high-income countries.21 
Moreover, 500 mg is a level of supplementation that is 
achievable with food fortification.22
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Panel: Outcomes and definitions
Primary outcome:
• Pre-eclampsia, defined as gestational hypertension and 
gestational proteinuria, as defined below, or diagnosed by 
the attending clinicians
Secondary outcomes:
• Pre-eclampsia or pregnancy loss, or both, at any 
gestational age
• Gestational hypertension (diastolic blood pressure 
>90 mm Hg on two occasions 4 h apart; or >110 mm Hg 
once, or systolic blood pressure >140 mm Hg on 
two occasions 4 h apart; or both, or >160 mm Hg once, after 
20 weeks’ gestation)
• Gestational proteinuria (2 or more on urine dipstick, or 
>300 mg/24 h, or >500 mg/L or urinary protein: creatinine 
ratio >0·034 g/mmol, after 20 weeks’ gestation
• Pregnancy loss at any gestational age, including miscarriage 
and stillbirth, excluding requested abortion
• No pregnancy during study period
• Severe gestational hypertension (systolic blood pressure 
>160 mm Hg on two occasions 4 h apart, or once followed 
by antihypertensive therapy, or diastolic blood pressure 
>110 mm Hg on two occasions 4 h apart, or once followed 
by antihypertensive therapy, after 20 weeks’ gestation)
• Early onset pre-eclampsia (<32 weeks’ gestation)
• Severe pre-eclampsia (proteinuria plus severe diastolic 
[>110 mm Hg] or systolic [>160 mm Hg] hypertension)
• Moderately severe thrombocytopenia (<100 × 10⁹/L)
• Uric acid more than reference values for gestational age
• Renal failure (creatinine >120 mmol/L)





• Intensive care unit admission >24 h
• HELLP syndrome
• Maternal death
• Participant hospital stay ≥7 days after childbirth
• Caesarean section
• Birthweight <2500 g
• Preterm birth (<37 weeks’ gestation)
• Early preterm birth (<32 weeks’ gestation)
• Apgar score <7 at 5 min
• Perinatal death or admission to neonatal intensive care unit 
for 24 h or more
• Stillbirth
• Pregnancy loss, stillbirth, or neonatal death before discharge
• Pregnancy loss, stillbirth, or neonatal death before 6 weeks
• Previous WHO calcium trial composites (severe pre-eclamptic 
complications index* and severe maternal morbidity and 
mortality index†) and compliance outcomes (proportion of 
expected tablet intake based on counts of returned tablets)4
HELLP syndrome=haemolysis, elevated liver enzymes, and low platelet count. *Severe 
pre-eclamptic complications index: severe pre-eclampsia, early-onset pre-eclampsia 
(<32 weeks’ gestation), eclampsia, HELLP syndrome, placental abruption, or severe 
gestational hypertension. †Severe maternal morbidity and mortality index: maternal 
admission to intensive care, eclampsia, severe pre-eclampsia, placental abruption, HELLP 
syndrome, renal failure, or death.
In addition to receiving the allocated calcium or placebo 
tablets until 20 weeks’ gestation, all participants also 
received calcium supplementation as recommended by 
WHO (1·5 g elemental calcium daily) from 20 weeks’ 
gestation until childbirth.23
Once recruited, participants were asked to return to the 
clinic-based research office every 12 weeks until pregnant, 
and then every 12 weeks until childbirth for follow-up 
visits. The visits during pregnancy were scheduled to take 
place as close as possible to 8 weeks’, 20 weeks’, and 
32 weeks’ gestation, alongside the routine antenatal care 
visits. Contact was maintained by 4-weekly telephone calls.
After participants had given birth, members of the 
research team extracted their outcome data from 
hospital records. At 6 weeks after childbirth, participants 
were telephoned to enquire about any complications 
since discharge from hospital. Participants who entered 
the trial and did not become pregnant were followed up 
for 1 month after cessation of calcium supplements.
Data were recorded on case report forms specifically 
designed for the trial and entered in duplicate in a web-
based data management system (OpenClinica). Blood 
pressure was recorded using mercury sphygmoman-
ometers at the African sites, and with electronic blood 
pressure monitors in Argentina. All members of the 
research team were trained and assessed on their ability 
to measure blood pressure, with the British Hypertension 
Society training materials. Blood pressure measurements 
were standardised in the following way: participants 
were at rest, having been seated for 5 min or in bed with 
their abdomen tilted at least 30° to the left; the cuff was 
placed on the right arm at the level of the heart; two 
blood pressure measurements (systolic and diastolic) 
were taken at 3-min intervals; diastolic blood pressure 
was measured at the fifth Korotkoff sound (disappearance 
of the sounds); and the average of the two readings was 
recorded.
This was a pragmatic trial and, therefore, pre-eclampsia 
was recorded as an outcome if it was diagnosed by a 
health-care provider and recorded in the participant’s 
medical records or if we identified both high blood 
pressure and proteinuria, as per the trial definitions of 
pre-eclampsia, in a participant’s medical records.
Urine was collected routinely from all participants 
during trial antenatal visits, on admission in labour, or 
before elective caesarean section, to detect the presence 
of protein with a dipstick. This process was in accordance 
with routine clinical practice at the study sites.
For OpenClinica see 
www.openclinica.com
For British Hypertension Society 
see http://bhsoc.org/
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Results of relevant laboratory investigations during 
the provision of routine care, such as blood haemo-
globin concentrations, were recorded in the case report 
forms, and for those who developed pre-eclampsia, 
these usually included a blood platelet count, serum 
urate, urea, creatinine, and liver function tests (ie, lactate 
dehydro genase, alanine aminotransferase and aspar-
tate amino trans ferase, and a urine protein:creatinine 
ratio, urine protein, or 24 h urinary protein investi-
gation, or both). Where several tests had been done, 
the last test before labour or caesarean section was 
used or, if none had been done previously, the first 
test after the start of labour or caesarean section was 
used.
In a substudy done at all the African sites, data 
on dietary intake were obtained from participants at 
20 weeks’ gestation, using a triple pass 24 h dietary 
recall ques tionnaire.24 A detailed description of the 
methodol ogy and analysis of these findings has been 
published else where.25 Diet assessment at 20 weeks’ 
gestation showed a mean daily calcium intake of 441 mg 
per day (SD 87·7; n=224) in South African women and 
360·5 mg per day (SD 171·4; n=88) in Zimbabwean 
women, confirming the very low dietary calcium intake 
among trial participants.
Every 12 weeks during trial follow-up visits both before 
and during pregnancy, all returned, unused tablets were 
counted, and the number assumed to have been taken 
was calculated and recorded. Treatment compliance was 
calculated by dividing the number of used tablets by the 
total number of tablets that should have been taken since 
the last count. A new bottle of 84 tablets was supplied to 
participants and returned tablets were stored until the 
end of the trial.
Outcomes
The original protocol registered with the Pan-African 
Clinical Trials Registry identified three primary outcomes: 
pre-eclampsia, pre-eclampsia or pregnancy loss before 
labour at any gestation, and severe maternal morbidity 
and mortality index: defined as one or more of the 
specified secondary outcomes. The reason for the second 
primary outcome was to account for possible confounding 
of the pre-eclampsia outcome by pregnancy loss, which 
might be causally related. Before trial com mencement, 
we revised the protocol to specify only the first primary 
outcome.
Our primary outcome was therefore pre-eclampsia, de-
fined as gestational hypertension and proteinuria (see the 
panel for definitions). A full list of secondary outcomes 
can be found in the panel.
Statistical analysis
The sample size calculation was informed by the WHO 
trial of calcium supplementation in the second half of 
pregnancy, where hypertension occurred in 14% of the 
relatively low-risk participants who received calcium 
supplementation from 20 weeks’ gestation.16 The risk 
of recurrent pre-eclampsia for women with previous pre-
eclampsia or eclampsia is estimated to be at least 25%.26 
We calculated that, to show a reduction in pre-eclampsia 
from 25% to 15%, we would need 540 participants 
with pregnancies continuing beyond 20 weeks’ gestation 
(0∙05 α level, 80% power; calculated using Epi Info 
software (CDC, Atlanta, GA, USA). We anticipated that 
50% of participants recruited would become pregnant 
during the trial. Allowing for a miscarriage rate of 
15% and loss to follow-up of 10%, we needed to recruit 
approximately 1440 participants who were not pregnant. 
Enrolment would be stopped once we were able 
to predict reaching our primary sample size (ie, the 
540 participants with pregnancies continuing beyond 
20 weeks’ gestation).
Analyses of the effects of the intervention were in-
tention to treat (ITT), irrespective of supplementa tion 
compliance. We prepared a table of baseline char-
acteristics of the study groups for all participants 
enrolled and also for those in the final study sample 
Figure: Study profile
*Eight subjects were randomised but not eligible.




678 allocated prepregnancy calcium supplementation 677 allocated placebo
347 excluded due to:
149 did not conceive during study
157 lost to follow-up before conception
41 withdrew before conception 
357 excluded due to:
167 did not conceive during study
163 lost to follow-up before conception
27 withdrew before conception
331 conceived during study 320 conceived during study
2 lost to follow-up after 20 weeks 0 lost to follow-up after 20 weeks
296 analysed 283 analysed
298 follow-up after 20 weeks 283 follow-up after 20 weeks
33 excluded due to:
1 lost to follow-up before 20 weeks
27 pregnancy loss before 20 weeks
5 abortion requested before 20 weeks
0 discontinued while pregnant
37 excluded due to:
4 lost to follow-up before 20 weeks
27 pregnancy loss before 20 weeks
5 abortion requested before 20 weeks 
1 discontinued while pregnant
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(participants ≥20 weeks’ gestation) to make sure that 
exclusion of those who did not have a pregnancy until 
20 weeks did not compromise ran domisation. Among 
those lost to follow-up, the number of participants lost, 
and their baseline char acteristics, were compared to 
exclude any imbalances between study groups (data not 
shown). We also did a pre specified per-protocol analysis 
for participants for whom compliance with calcium 
supple mentation was more than 80%. Other prespecified 
sub group analyses are still to be done and will be 
reported in a separate paper.
For categorical variables, we calculated the number of 
participants, number of missing values and percentages, 
and for continuous variables, we calculated the number 
of participants, number of missing values, minima, maxi-
ma, means, and SDs. Categorical variables were compared 
as risk ratios (RR) with 95% CIs.
In this study, randomisation took place before con-
ception, yet exposure to the primary outcome was 
limited to those who conceived and carried a pregnancy 
con tinuing beyond 20 weeks’ gestation during the 
study period. There fore, we anticipated potential con-
founders by first com paring the rates of pregnancy 
between study groups, for which we used a χ² test. Had 
a difference in pregnancy rates been found, all sub-
sequent analyses would have been done with the total 
enrolment numbers for each group as denominators, 
as well as with the numbers who became pregnant 
as denominators, and the effect of the differential rates 
of pregnancy on the results explored. A more likely 
confounder anticipated was early pregnancy loss, as the 
same pathology might cause both early pregnancy loss 
and pre-eclampsia. Any reduction in early pregnancy 
loss owing to calcium supple mentation might increase 
the proportion of partici pants diagnosed with pre-
eclampsia. For this reason we included the composite 
secondary outcome, pre-eclampsia or pregnancy loss, 
or both.
Calcium group (n=678) Placebo group (n=677) p value
No pregnancy 347 (51%) 357 (53%) 0·567
Pregnancy loss <20 weeks’ gestation* 32 (5%) 32 (5%) 1·000
Pregnancy ≥20 weeks’ gestation 298 (44%) 283 (42%) 0·420
Livebirth 249 (37%) 228 (34%) 0·240
*Data include five participants in each group who elected to have an abortion.









From randomisation up to the last 
visit before pregnancy*
100/213 (47%) 100/208 (48%) 0·98 (0·80–1·19) 0·817
From last visit before pregnancy 
to the 20-week visit†
145/274 (53%) 149/269 (55%) 0·96 (0·82–1·12) 0·563
Compliance >50%
From randomisation up to the last 
visit before pregnancy*
173/213 (81%) 187/208 (90%) 0·90 (0·83–0·98) 0·011
From last visit before pregnancy 
to the 20-week visit†
212/274 (77%) 218/269 (81%) 0·95 (0·88–1·04) 0·292
Data are n/N (%), unless otherwise specified. *For women with no visit before pregnancy because they became 
pregnant before 3 months after admission, we have used the admission visit as surrogate. †For women with no 
pregnancy visit at 20 weeks’ gestation (n=63) the data from the nearest visit to 20 weeks was used: as first option the 
32-week visit (ten cases) and as a second option the 8-week visit (15 cases).
Table 2: Compliance of participants in the final sample (pregnancy ≥20 weeks’ gestation)
All participants at trial entry (n=1355) Participants with pregnancy ≥20 weeks’ gestation (n=581)
Calcium (n=678) Placebo (n=677) Calcium (n=298) Placebo (n=283)
Maternal age, years 678 (30·2) [5·8] 677 (30·4) [5·9] 298 (29·4) [5·4] 283 (29·2) [5·1]
Maternal age <20 years 10/678 (2%) 14/677 (2%) 6/298 (2%) 5/283 (2%)
Maternal weight, kg 649/678 (76·2) [18·5] 641/677 (76·9) [18·8] 289/298 (75·7) [17·6] 276/283 (75·7) [17·4]
Maternal height, cm 617/678 (160·2) [6·3] 613/677 (160) [6·7] 277/298 (160·4) [6·2] 260/283 (159·9) [6·5]
Body mass index, kg/m2 610/678 (29·7) [7·1] 608/677 (30·1) [6·9] 273/298 (29·5) [6·8] 258/283 (29·6) [6·6]
Body mass index >30 kg/m2 263/610 (43%) [43·1] 268/608 (44%) [44·1] 114/273 (42%) [41·8] 109/259 (42%) [42·1]
Systolic blood pressure at 
randomisation, mm Hg
675/678 (127·0) [19·3] 674/677 (127·3) [19·2] 297/298 (126.0) [17·3] 283/283 (126·1) [18·8]
Diastolic blood pressure at 
randomisation, mm Hg
675/678 (81·6) [14·1] 674/677 (82·3) [13·9] 297/298 (81·2) [12·8] 283/283 (81·7) [13·7]
Any health complaint at randomisation 20/678 (3%) 23/677 (3%) 5/298 (2%) 6/283 (2%)
Previous severe pre-eclampsia* 309/403 (77%) 343/414 (83%) 151/188 (80%) 152/178 (85%)
Previous eclampsia 107/643 (17%) 103/639 (16%) 51/284 (18%) 53/266 (20%)
Previous HELLP syndrome 69/561 (12%) 78/561 (14%) 34/251 (14%) 40/229 (18%)
Previous livebirth 349/678 (52%) 337/677 (50%) 129/298 (43%) 118/283 (42%)
Data are in n/N (%) or n/N (mean [SD]). HELLP=haemolysis, elevated liver enzymes, and low platelet count. *Defined as systolic blood pressure ≥160 mm Hg or diastolic 
blood pressure ≥110 mm Hg.
Table 1: Baseline characteristics of participants at trial entry (pre pregnancy sample) and of the final sample (pregnancy ≥20 weeks’ gestation) according 
to study group
Articles
336 www.thelancet.com   Vol 393   January 26, 2019
SPSS (version 22) and R (version 3.3.0) were used for all 
statistical analyses. All tests were done using the usual 
two-sided, 5% significance levels. The study was overseen 
by the Data Safety and Monitoring Committee.
The trial was registered with the Pan-African Clinical 
Trials Registry on Dec 6, 2010, registration number 
PACTR201105000267371.
Role of the funding source
The funders of the trial had no role in the trial de-
sign, data collection, data analysis, data interpretation, or 
writing of the report. The primary author, GJH, has full 
access to all the data in the trial and had the final 
responsibility for the decision to submit for publication. 
Midway through the study, the study team was app-
roached by Alternative Discovery & Development, 
GlaxoSmithKline Medicines Research Centre, UK, who 
partnered with us to collect blood samples from a sub-
group of participants in our trial for an independent, 
open-innovation pre-eclampsia biomarker study, follow-
ing a separate protocol which was approved by the trial 
ethics committee. Apart from direct funding to the 
largest site (Chris Hani Baragwanath Hospital) speci-
fically for the costs of this blood sample collection, 
GSK provided no funding to the main trial and did not 
participate in any aspect of the main trial.
Calcium group (n/N [%]) Placebo group (n/N [%]) RR (95% CI) p value
Pre-eclampsia (primary outcome) 69/296 (23%) 82/283 (29%) 0·80 (0·61–1·06) 0·121
Pre-eclampsia (as a proportion of all women randomised) 69/678 (10%) 82/677 (12%) 0·84 (0·62–1·14) 0·258
Pre-eclampsia and or pregnancy loss at any gestation* 107/323 (33%) 126/310 (41%) 0·82 (0·66–1·00) 0·050
Gestational hypertension 194/296 (66%) 197/283 (70%) 0·94 (0·84–1·05) 0·296
Gestational proteinuria 78/296 (26%) 90/283 (32%) 0·83 (0·64–1·07) 0·149
Pregnancy loss at any gestation* 58/323 (18%) 67/310 (22%) 0·83 (0·61–1·14) 0·248
No pregnancy during the study period† 347/678 (51%) 357/677 (53%) 0·97 (0·88–1·08) 0·567
Severe gestational hypertension 93/296 (31%) 94/283 (33%) 0·95 (0·75–1·20) 0·644
Early onset pre-eclampsia (<32 weeks’ gestation) 37/296 (13%) 38/283 (13%) 0·93 (0·61–1·42) 0·740
Severe pre-eclampsia 52/296 (18%) 60/283 (21%) 0·83 (0·59–1·16) 0·268
Moderately severe thrombocytopenia 13/63 (21%) 12/74 (16%) 1·27 (0·63–2·59) 0·505
Uric acid greater than reference values for gestational age 22/27 (82%) 19/24 (79%) 1·03 (0·78–1·35) 0·835
Renal failure (creatinine >120 mmol/L) 7/58 (12%) 5/68 (7%) 1·64 (0·55–4·90) 0·369
Liver failure 8/53 (15%) 7/63 (11%) 1·36 (0·53–3·50) 0·524
Eclampsia‡ 4/296 (1%) 5/283 (2%) 0·76 (0·21–2·82) 0·747
Placental abruption 9/295 (3%) 5/283 (2%) 1·73 (0·59–5·09) 0·420
Pulmonary oedema 0/296 (0%) 1/283 (0%) 0 0·489
Stroke 0/296 (0%) 0/283 (0%) ·· ··
ICU admission >24 h 2/296 (1%) 3/283 (1%) 0·64 (0·11–3·79) 0·680
HELLP syndrome 10/69 (15%) 7/81 (9%) 1·68 (0·67–4·17) 0·260
Maternal death* 2/323 (1%) 2/310 (0%) 0·96 (0·14–6·77) 1·00
Participant hospital stay 7 days or more after birth 23/292 (8%) 13/282 (5%) 1·71 (0·88–3·31) 0·107
Caesarean section 176/295 (60%) 152/283 (54%) 1·11 (0·96–1·28) 0·149
Birthweight <2500 g 79/264 (30%) 73/243 (30%) 1·00 (0·76–1·30) 0·977
Preterm birth (<37 weeks’ gestation) 112/296 (38%) 119/283 (42%) 0·90 (0·74–1·10) 0·301
Early preterm birth (<32 weeks’ gestation) 47/296 (16%) 57/283 (20%) 0·79 (0·56–1·12) 0·182
Apgar score <7 at 5 min 5/255 (2%) 11/239 (5%) 0·43 (0·15–1·21) 0·097
Perinatal death or admission to neonatal ICU for 24 h or more 52/265 (20%) 43/243 (18%) 1·11 (0·77–1·60) 0·578
Stillbirth 27/296 (9%) 33/283 (12%) 0·78 (0·48–1·27) 0·316
Pregnancy loss, stillbirth, or neonatal death before discharge* 65/323 (20%) 76/309 (25%) 0·82 (0·61–1·10) 0·177
Pregnancy loss, stillbirth, or neonatal death before 6 weeks* 74/323 (23%) 80/309 (26%) 0·88 (0·67–1·16) 0·383
Severe pre-eclamptic complications index§ 106/296 (36%) 103/283 (36%) 0·98 (0·79–1·22) 0·884
Severe maternal morbidity and mortality index¶ 63/296 (21%) 65/283 (23%) 0·93 (0·68–1·26) 0·625
RR=risk ratio. ICU=intensive care unit. HELLP=haemolysis, elevated liver enzymes, and low platelet count. The denominator for all outcomes includes pregnant participants 
who reached ≥20 weeks’ gestation, with the exception of outcomes denoted by * or †. *The denominator includes participants that became pregnant during the study 
period, excluding those who requested an abortion (five in each group), withdrew (one in each group), or were lost to follow-up before 20 weeks’ gestation (one in calcium 
group and four in placebo group). †The denominator includes all randomised participants. ‡All participants with eclampsia also had pre-eclampsia. §Severe pre-eclamptic 
complications index includes any of the following: severe pre-eclampsia, early-onset pre-eclampsia, eclampsia, placental abruption, HELLP syndrome, or severe gestational 
hypertension. ¶Severe maternal morbidity and mortality index includes any of the following: admission to ICU or any special care unit, eclampsia, placental abruption, HELLP 
syndrome, renal failure, or death.
Table 4: Primary and secondary outcomes according to study group
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Results
Between July 12, 2011, and Sept 8, 2016, 2563 women 
were screened, 1355 were recruited and randomly 
assigned (678 calcium, 677 placebo), and 651 became 
pregnant (331 calcium, 320 placebo), among whom 
581 had a pregnancy continuing beyond 20 weeks’ gesta-
tion (298 calcium, 283 placebo). Two participants in the 
calcium group were lost to follow up after 20 weeks’ 
gestation; therefore, 579 participants contributed data to 
the final outcome analyses (296 calcium, 283 placebo). 
Eight participants who did not meet all eligibility criteria 
were randomly assigned in error; these patients were 
included in the analysis. Four of them had a pregnancy 
beyond 20 weeks’ gestation two in each group (figure). 
The trial closed on Oct 31, 2017. Among the 581 participants 
with pregnancies continuing beyond 20 weeks’ gesta-
tion, 26 were in Argentina, 160 in Zimbabwe, and 395 in 
South Africa.
Baseline characteristics of participants were similar in 
the two study groups at trial entry (table 1). The largest 
discrepancy was in previous severe pre-eclampsia, which 
was assumed to be a chance discrepancy among many 
parameters, as the randomisation procedure was robust. 
Baseline characteristics were similar for the final sample, 
suggesting that randomisation was not compromised 
by discrepancies between groups comprising the final 
sample (table 1).
Compliance data were available for 421 (73%) of 
581 participants from recruitment until the last visit 
before pregnancy, and for 543 (93%) of 581 of women 
from the last visit before pregnancy until 20 weeks’ 
gestation (table 2). For those with data available, about 
half the participants took at least 80% of the expected 
tablets (53% calcium, 55% placebo) from the last visit 
before pregnancy to 20 weeks’ gestation. In our analysis 
plan, we regarded this period as most relevant to the trial 
intervention.
None of the pregnancy outcomes were significantly 
different between groups (table 3).
For the primary outcome, the prevalence of pre-
eclampsia was lower in the calcium group (69 [23%] 
of 296 vs 82 [29%] of 283, a reduction of 20%); how-
ever, the difference was not significant (RR 0·80 [95% CI 
0·61–1·06]; p=0·121; table 4). There were no significant 
differences in secondary outcomes. The prevalence of 
pre-eclampsia or pregnancy loss, or both, was 33% in 
the calcium group and 41% in the placebo group 
(RR 0·82 [95% CI 0·66–1·00]; p=0·050), which was 
of borderline significance. There were no significant 
differences in the composite outcomes defined in the pre-
vious WHO trial on calcium supplementation,16 namely 
severe maternal morbidity and mortality index and 
sev ere pre-eclamptic index. Per-protocol analysis done for 
participants with compliance of more than 80% from the 
last visit before pregnancy to 20 weeks’ gesta tion was 
consistent with the main trial findings on pre-eclampsia, 
with fewer participants in the calcium group (30 (21%) 
of 144) than in the placebo group (47 [32%] of 149) 
developing pre-eclampsia (RR 0·66, CI 0·44–0·98; 
p=0·037, table 5). The other pre-specified subgroup and 
exploratory analyses will be reported separately.
Serious adverse events were systematically recorded. 
Most were classified as unrelated to the intervention, 
none were related or likely related, and in five of 
82 women in the calcium group and 12 of 79 in the 
placebo group, a serious adverse event was classified as 
unlikely related. 12 participants died during the 6-year 
trial period (five calcium, seven placebo; appendix). Of 
these par ticipants, eight did not become pregnant and 
four died within 6 weeks of childbirth (two calcium, 
two placebo). One death (in the placebo group) was 
associated with hypertension. We were informed of one 
further death outside of the trial period (more than 
6 weeks after completion of a pregnancy). No deaths 
were trial-related.
Discussion
This trial does not show a significant reduction in 
recurrent pre-eclampsia with calcium supplementation 
before and during early pregnancy. This trial is fun-
damentally different from previous trials of calcium to 
prevent pre-eclampsia. We sought a specific effect of cal-
cium in early pregnancy (when defective placentation is 
thought to initiate the pre-eclampsia pathway) on the 
evolution of pre-eclampsia in late pregnancy despite high-
dose calcium supplementation from 20 weeks’ gestation 
in both study groups, as recommended by WHO.22 The 
trial was designed to detect a 40% reduction in pre-
eclampsia and the results do not show a large effect size. 
Possible reasons include the following: there is no real 
effect; there is a real effect but it is smaller than the 40% 
for which the trial was powered, because of a type 2 
statistical error (of which there was a 20% risk); or because 
suboptimal compliance diluted the effect. The finding 
of a greater reduction in pre-eclampsia with calcium 
supplementation in the per-protocol analysis for those 
participants with compliance of more than 80% suggests 
that suboptimal compliance might have played a part.
The composite secondary outcome pre-eclampsia or 
pregnancy loss, or both, merits discussion because preg-
Calcium (n/N [%]) Placebo (n/N [%]) Risk ratio 95% CI p value
Compliance >80% from randomisation up to the last PPV
Pre-eclampsia* 20/98 (20%) 33/100 (33%) 0·62 (0·38–1·00) ·· 0·045
Compliance >80% from last PPV to the 20-week visit
Pre-eclampsia† 30/144 (21%) 47/149 (32%) 0·66 (0·44–0·98) ·· 0·037
Compliance >80% from randomisation up to the last PPV and compliance >80% from last PPV to the 
20-week visit
Pre-eclampsia 14/69 (20%) 23/72 (32%) 0·64 (0·36–1·13) ·· 0·116
PPV=prepregnancy visit. *98 in the calcium group, because one participant was not eligible and one was lost to 
follow-up. †144 in the calcium group because one participant was not eligible. 
Table 5: Per-protocol analysis of the primary outcome for participants with >80% compliance
See Online for appendix
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nancy loss and pre-eclampsia might have an association. 
This outcome might overcome confounding of pre-
eclampsia findings by an early effect of calcium on 
pregnancy loss, and might be a better indicator of the 
overall effect of calcium supplementation. With calcium 
supplementation, we found an 18% reduction in this 
outcome (95% CI 0–34), which was of borderline 
statistical significance (p=0·050).
The numbers of serious outcomes were too small for 
meaningful statistical analysis. The low prevalence of 
severe complications is to be expected, as both groups 
received high-dose calcium from 20 weeks’ gestation, 
which is known to reduce the severe complications of 
pre-eclampsia. The high quality of care received as a result 
of participation in the trial might also have contributed 
to reducing poor outcomes, as illustrated by the fact 
that, despite there being a high prevalence of previous 
eclampsia (19%) in the overall sample, only 1·4% of 
participants in the calcium group and 1·8% in the placebo 
group developed eclampsia during the trial.
The intervention in our study was purposefully of 
a low intensity: a low dose of calcium (500 mg daily) 
was used because a higher dose, even if effective, would 
not be implementable on a broad scale, such as through 
food fortification. The randomised intervention stopped 
at 20 weeks’ gestation, thus the effect was limited to pre-
pregnancy and early pregnancy calcium effects, avoiding 
confounding by the known beneficial effects of calcium 
later in pregnancy. Our study would thus have under-
estimated the overall effect of calcium supple mentation 
throughout pregnancy, which could be extrapolated to be 
the summation of any effects of supplementation before 
and in early pregnancy plus the effects of supplementation 
after 20 weeks as measured by previous trials.17
To our knowledge, this is the first trial attempting to 
measure the effects of calcium supplementation before 
conception and measuring the effect on pregnancy 
outcomes. Despite the challenges of this type of trial, the 
research team managed to recruit and retain sufficient 
participants over a long period of time. The strategies put 
in place leading to this success have been described 
elsewhere.23 One previous study of calcium supple-
mentation in early pregnancy has been reported.27 This 
small RCT evaluated calcium and antioxidant supple-
mentation commenced at 8–12 weeks’ gestation compared 
with placebo and found reductions in pre-eclampsia 
(two of 29 in the calcium group vs nine of 31 in the placebo 
group) and miscarriage (zero of 29 vs eight of 31) with the 
intervention; the results are suggestive of a calcium effect 
because antioxidants have not been found to reduce 
pre-eclampsia.28
During recruitment, the diagnosis of previous pre-
eclampsia was in accord with the hospital records in most 
cases. However, if the record was not available, we relied 
on the information reported by participants in this respect. 
Although we are confident that women in these setting 
are aware of their diagnosis when they have pre-eclampsia 
or eclampsia, we cannot exclude the possibility of errors. 
Such errors might have diluted the level of risk in 
both groups but would not affect the comparability of 
the groups.
The study groups were comprised of participants from 
a population with generally low dietary calcium intake 
and, therefore, the effects of calcium supplementation 
might not be generalisable to women with adequate 
dietary intake. In addition, the study participants were at 
high risk of pre-eclampsia on the basis of their having a 
previous diagnosis of pre-eclampsia. A general obstetric 
population would include women at varying and often 
unpredictable risk of pre-eclampsia.
Calcium supplementation commenced before preg-
nancy until 20 weeks’ gestation, compared with placebo, 
did not show a significant reduction in recurrent pre-
eclampsia. As the trial was powered to detect a large 
effect size, we cannot rule out a small to moderate effect 
of this intervention.
Calcium supplementation is recommended by WHO 
from 20 weeks of pregnancy at doses of 1·5–2·0 g per day, 
particularly in a population with low calcium intake.22 
Dietary calcium intake in low-income settings is typically 
exceptionally poor.16 The cost of one tablet daily (600 mg) 
is estimated to cost under US$8 per person per year.29 
Findings from our study, with appropriate recognition of 
the absence of significance, should be considered together 
with all other available evidence on the benefits of adequate 
calcium intake for pregnant women and the general 
population, in determining the cost and benefits of 
strategies to improve calcium intake at a population level.
The findings of this complex and lengthy trial suggest 
that a larger trial would be required to adequately test a 
small to moderate effect of calcium on pre-eclampsia. 
Researchers and policymakers will need to evaluate 
whether further research, possibly using a population-
based approach, is justified.
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